Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-23T16:31:50.471Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia

Published online by Cambridge University Press:  01 September 2022

N. Uhrenholt ,
A. Ganeshalingam ,
S. Arnfred ,
J. Frystyk ,
P. Gæde  and
N. Bilenberg
N. Uhrenholt*
Affiliation:
Psychiatry West, Region Zealand, Research Unit For Psychotherapy And Psychopathology, Slagelse, Denmark
A. Ganeshalingam
Affiliation:
Odense University Hospital., Department Of Endocrinology M / Steno Diabetes Centre Odense (sdco), Odense, Denmark
S. Arnfred
Affiliation:
Psychiatry West, Region Zealand, Research Unit For Psychotherapy And Psychopathology, Slagelse, Denmark
J. Frystyk
Affiliation:
Odense University Hospital., Department Of Endocrinology M / Steno Diabetes Centre Odense (sdco), Odense, Denmark
P. Gæde
Affiliation:
Næstved, Slagelse og Ringsted Hospital, Department Of Cardiology And Endocrinology, Slagelse, Denmark
N. Bilenberg
Affiliation:
Mental Health Services in the Region of Southern Denmark, Child And Adolescent Psychiatry Odense, Odense C, Denmark
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Life expectancy of people with schizophrenia is reduced by 10-20 years compared to the general population. The excess mortality is part due to an increased prevalence of cardiovascular disease, prediabetes and obesity, which are in part due to antipsychotic treatment. Gaining weight is associated with reduced quality of life and also among the most frequently reported reasons for the discontinuation of treatment. Lifestyle changes have a time limited effect, and therefore, interest has focused on Glucagon-Like Peptide 1 receptor agonist treatment. Semaglutide, currently used to treat type 2-diabetes in doses up to 1.0 mg once-weekly, has shown promising results regarding weight loss in doses up to 2.4 mg once-weekly. It may also be able to reduce the risk of developing diabetes and cardiovascular disease.

Objectives

The HISTORI Trial aims to reduce risk of developing diabetes and cardiovascular disease in people with schizophrenia, prediabetes and overweight and to investigate for an indirect effect of Semaglutide on psychotic symptoms and quality of life through a weight loss.

Methods

A 30 weeks randomized, placebo-controlled, double-blinded study with once-weekly injections of Semaglutide 1.0 mg. Primary inclusion criteria are age 18-40 years, schizophrenia, prediabetes, overweight and treatment with antipsychotics. Questionnaires and interviews regarding psychotic symptoms, quality of life, medication adherence and physical activity will be applied either monthly or every third month.

Results

will not be ready for the congress. A poster outlining the feasibility challenges will be presented.

Conclusions

Perspective: Through weight loss, Semaglutide may indirectly be able to improve quality of life, medication adherence and psychotic symptoms.

Disclosure

No significant relationships.

Keywords

schizophréniaPrediabetesGlucagon-Like Peptide 1Positive and negative symptoms (PANSS)
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S798 - S799
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.